Skip to main content
Premium Trial:

Request an Annual Quote

Invitrogen to Screen Drug Targets for Chroma Therapeutics

NEW YORK (GenomeWeb News) – Invitrogen said today it will continue to screen kinase inhibitors for Chroma Therapeutics after the companies extended an earlier agreement.
 
Invitrogen will use its SelectScreen service at its facility in Paisley, Scotland, to screen targets, study phylogenetic diversity, and explore signaling pathways to help Chroma Therapeutics “rapidly confirm the selectivity and potency of our small-molecule drugs,” Chroma Therapeutics CSO Alan Drummond said in a statement.
 
Drummond said Invitrogen’s kinases allow his company to determine if drug candidates are inhibiting the targeted kinases and how they interact with other kinases, and to predict potential side effects.
 
The agreement extends an earlier one between the companies that has been ongoing for over a year.
 
Financial terms of the agreement were not released.

The Scan

Just Breathing

A new analysis suggests that most Mycobacterium tuberculosis is spread by aerosols from breathing, rather than by coughing, the New York Times reports.

Just Like This One

NPR reports that the World Health Organization has hired a South African biotech company to recreate mRNA vaccine for SARS-CoV-2 that is similar to the one developed by Moderna.

Slow Start

The Wall Street Journal reports that Biogen's Alzheimer's disease treatment had revenues for July through September that totaled $300,000.

Genome Research Papers on Cancer Chromatin, Splicing in the Thymus, Circular RNAs in Cancer

In Genome Research this week: analysis of bivalent chromatin sites, RBFOX splicing factors' role in thymic epithelial cells, and more.